Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386388082> ?p ?o ?g. }
- W4386388082 endingPage "264" @default.
- W4386388082 startingPage "255" @default.
- W4386388082 abstract "Abstract Background and Objectives Acute graft-versus-host disease (aGvHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methylprednisolone (MP; 1–2 mg/kg/day) remains the standard first-line therapy for aGvHD, although no response is detected in nearly one-half of the patients with aGvHD. This study aimed to investigate the feasibility of mini-dose methotrexate (MTX) combined with standard-dose MP as a front-line therapy for aGvHD. Materials and Methods A prospective Phase 2 clinical trial was performed to evaluate the safety and efficacy of 5 mg/m2 MTX combined with 1 mg/kg/day MP as the initial therapy in 31 patients with aGvHD. Moreover, the effects of MTX combined with MP were explored in a humanized xenogeneic murine model of aGvHD. Results The overall response and complete response rate at 7 days after the initial treatment were 100% and 83%, respectively. The overall response rate on day 28 was 87%. The complete response rates for aGvHD grades I, II, and III were 100% (6/6), 82% (18/22), and 66% (2/3), respectively. Grade 3 toxicities occurred in only three patients presenting with cytopenia. Importantly, MTX and MP demonstrated synergistic effects on ameliorating aGvHD in humanized xenogeneic murine model. Conclusion The current study suggests that mini-dose MTX combined with standard-dose MP could potentially become a novel first-line therapy for patients with aGvHD." @default.
- W4386388082 created "2023-09-03" @default.
- W4386388082 creator A5009934914 @default.
- W4386388082 creator A5015107448 @default.
- W4386388082 creator A5037029781 @default.
- W4386388082 creator A5043041637 @default.
- W4386388082 creator A5046756784 @default.
- W4386388082 creator A5060211823 @default.
- W4386388082 creator A5061407928 @default.
- W4386388082 creator A5062474943 @default.
- W4386388082 creator A5065894155 @default.
- W4386388082 creator A5081663648 @default.
- W4386388082 creator A5089572713 @default.
- W4386388082 date "2023-09-01" @default.
- W4386388082 modified "2023-10-16" @default.
- W4386388082 title "Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial" @default.
- W4386388082 cites W1978635205 @default.
- W4386388082 cites W1979146420 @default.
- W4386388082 cites W1999557292 @default.
- W4386388082 cites W2000487018 @default.
- W4386388082 cites W2010018407 @default.
- W4386388082 cites W2037163385 @default.
- W4386388082 cites W2049460956 @default.
- W4386388082 cites W2049830391 @default.
- W4386388082 cites W2051146400 @default.
- W4386388082 cites W2060578002 @default.
- W4386388082 cites W2065197520 @default.
- W4386388082 cites W2081210808 @default.
- W4386388082 cites W2144192117 @default.
- W4386388082 cites W2157147843 @default.
- W4386388082 cites W2294760333 @default.
- W4386388082 cites W2341901432 @default.
- W4386388082 cites W2581985817 @default.
- W4386388082 cites W2595681737 @default.
- W4386388082 cites W2760996153 @default.
- W4386388082 cites W2769990542 @default.
- W4386388082 cites W2789496953 @default.
- W4386388082 cites W2805930313 @default.
- W4386388082 cites W2890931670 @default.
- W4386388082 cites W3003169332 @default.
- W4386388082 cites W3004031232 @default.
- W4386388082 cites W3012634733 @default.
- W4386388082 cites W3015136999 @default.
- W4386388082 cites W3017383148 @default.
- W4386388082 cites W3034809027 @default.
- W4386388082 cites W3034963696 @default.
- W4386388082 cites W3047899229 @default.
- W4386388082 cites W3172965236 @default.
- W4386388082 cites W3200019819 @default.
- W4386388082 cites W4226183227 @default.
- W4386388082 cites W4297199855 @default.
- W4386388082 doi "https://doi.org/10.2478/jtim-2023-0111" @default.
- W4386388082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37662885" @default.
- W4386388082 hasPublicationYear "2023" @default.
- W4386388082 type Work @default.
- W4386388082 citedByCount "0" @default.
- W4386388082 crossrefType "journal-article" @default.
- W4386388082 hasAuthorship W4386388082A5009934914 @default.
- W4386388082 hasAuthorship W4386388082A5015107448 @default.
- W4386388082 hasAuthorship W4386388082A5037029781 @default.
- W4386388082 hasAuthorship W4386388082A5043041637 @default.
- W4386388082 hasAuthorship W4386388082A5046756784 @default.
- W4386388082 hasAuthorship W4386388082A5060211823 @default.
- W4386388082 hasAuthorship W4386388082A5061407928 @default.
- W4386388082 hasAuthorship W4386388082A5062474943 @default.
- W4386388082 hasAuthorship W4386388082A5065894155 @default.
- W4386388082 hasAuthorship W4386388082A5081663648 @default.
- W4386388082 hasAuthorship W4386388082A5089572713 @default.
- W4386388082 hasBestOaLocation W43863880821 @default.
- W4386388082 hasConcept C126322002 @default.
- W4386388082 hasConcept C141071460 @default.
- W4386388082 hasConcept C2777408962 @default.
- W4386388082 hasConcept C2779972918 @default.
- W4386388082 hasConcept C2780007613 @default.
- W4386388082 hasConcept C2780366003 @default.
- W4386388082 hasConcept C2780372218 @default.
- W4386388082 hasConcept C2781059491 @default.
- W4386388082 hasConcept C2911091166 @default.
- W4386388082 hasConcept C31760486 @default.
- W4386388082 hasConcept C535046627 @default.
- W4386388082 hasConcept C71924100 @default.
- W4386388082 hasConcept C90924648 @default.
- W4386388082 hasConceptScore W4386388082C126322002 @default.
- W4386388082 hasConceptScore W4386388082C141071460 @default.
- W4386388082 hasConceptScore W4386388082C2777408962 @default.
- W4386388082 hasConceptScore W4386388082C2779972918 @default.
- W4386388082 hasConceptScore W4386388082C2780007613 @default.
- W4386388082 hasConceptScore W4386388082C2780366003 @default.
- W4386388082 hasConceptScore W4386388082C2780372218 @default.
- W4386388082 hasConceptScore W4386388082C2781059491 @default.
- W4386388082 hasConceptScore W4386388082C2911091166 @default.
- W4386388082 hasConceptScore W4386388082C31760486 @default.
- W4386388082 hasConceptScore W4386388082C535046627 @default.
- W4386388082 hasConceptScore W4386388082C71924100 @default.
- W4386388082 hasConceptScore W4386388082C90924648 @default.
- W4386388082 hasIssue "3" @default.
- W4386388082 hasLocation W43863880821 @default.
- W4386388082 hasLocation W43863880822 @default.